    
    |
 |
Rufus
Scientific - company creation and interim management
Rufus Scientific
is about seeing where the exciting developments of the future lie, and
finding ways to exploit them. 'If you are so clever, why are you not doing
it for yourself?' is the usual response to such claims. Well, we do. William
Bains, Rufus founder and principal, has been intimately involved in creating
companies to exploit outstanding science and technological opportunities
for a decade. Below are some past and current involvements
|
|
|
Ark was founded
by Merlin Biosciences in 1998. William was the principle member of the
Merlin team writing the Series A business plan, and remained on the company's
scientific advisory board through 2000. Ark floated in March 2004.
|
|
|
|
|
ReNeuron
was another of the companies founded by Merlin. William identified ReNeuron's
core technology - neural stem cells - as a major new area of science at
a time when the concept was considered too 'science fiction' for commercial
exploitation. ReNeuron floated in 2001.. |
|
|
|
|
William
founded Amedis Pharmaceuticals in 2000, and was interim CEO/CSO until the
end of 2001. The company discovers new drugs based on silicon chemistry,
a scientifically radical idea William identified in 1998 as having a major
commercial opportunity. William took the company through seed and Series
A financing, recruitment of a management team, filing of initial patents,
setting up the first R&D programmes and closing the Company's first
pharmaceutical collaboration before leaving his executive role at the end
of 2002. William remains on the SAB. |
|
|
|
|
Delta
G is a new venture set up in 2003 to exploit higly innovative science in
bioenergetics - the understanding of how organisms generate energy from
food - and how they are related to diseases of ageing. Delta G is a 'systems
biology' company, moving beyond our understanding of biology from the genome
era. It was founded by William Bains, who is interim CEO. of the company.
|
|
|
|
|
Choracle
was founded in 2003 to build software to predict the biological properties
of chemicals, and is developing an initial product suite aimed at predicting
chemicals' toxicity. Choracle aims to be a profitable company by the end
of 2005 - a rarity in 'biotech'! Rufus provides scientific data and interim
management to Choracle. |
|
|
|
All
contents (c) William Bains 2004 unless specified otherwise.
|
